A 75-year-old man with Parkinson's disease, treated with co-careldopa, develops visual hallucinations. He is distressed by these but has no other features of delirium or psychosis. His Parkinson's motor symptoms are reasonably controlled. According to NICE NG71, what is the most appropriate initial management step regarding his medication?